New treatment approach boosts survival in young leukaemia patients
A recent clinical trial has shown that switching part of the standard chemotherapy protocol for a targeted immunotherapy significantly improves outcomes for young people living with acute lymphoblastic leukaemia (ALL). Nearly 89% of patients are still alive and cancer-free after three years of follow-up.